Press-release for stocks related to iot listed in the amex exchange

| 9.86% | O: -0.19% H: 1.49% C: 1.0%
GRMN | $142.51 1.06% 0.0% 780K

Electronic Technology

| -2.71% | O: -0.11% H: 0.39% C: 0.25%
GSAT | $1.3 3.18% -1.54% 2.1M

| -3.7% | O: 0.0% H: 9.63% C: 8.15%
integration iot satellite global smart

Satellite IoT Markets - Global Forecast to 2030: Growing Use of Satellite IoT Technology in Maritime Applications and Remote Areas Expected to Generate Growth Opportunities
Published: 2024-03-01 (Crawled : 20:00) - prnewswire.com
GSAT | $1.3 3.18% -1.54% 2.1M

| Email alert Add to watchlist
VOD | News | $8.685 0.75% 0.75% 4M

| Email alert Add to watchlist
IRDM | News | $28.76 2.31% 2.26% 1.6M

| Email alert Add to watchlist
maritime expected iot satellite global growing technology growth

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
Published: 2022-03-18 (Crawled : 11:00) - prnewswire.com
PLX | $1.2 1.7% 0.0% 270K

| 29.02% | O: 6.44% H: 11.11% C: 6.06%
prx-102 treatment rare trial therapeutics disease results iot prx012

Globalstar Appoints Telecom Leader Dave Haight to Drive IoT Growth
Published: 2022-03-08 (Crawled : 14:00) - investors.globalstar.com
GSAT | $1.3 3.18% -1.54% 2.1M

| 12.07% | O: -4.31% H: 7.21% C: 2.7%
als star growth iot

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease
Published: 2022-02-24 (Crawled : 12:30) - prnewswire.com
PLX | $1.2 1.7% 0.0% 270K

| 39.58% | O: -5.77% H: 3.69% C: 1.25%
prx-102 treatment europe application rare therapeutics disease authorization iot submission prx012

Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
Published: 2022-02-22 (Crawled : 18:00) - biospace.com/
AVEO | $15.0 0.0% 0

| 338.45% | O: -0.58% H: 1.18% C: -1.18%
ATNM | $6.96 -2.93% -1.14% 190K

| 37.01% | O: -1.18% H: 3.39% C: 0.2%
als solid tumors research therapy collaboration iot

Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
Published: 2022-01-05 (Crawled : 13:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K

| 10.3% | O: 0.0% H: 1.34% C: -7.45%
cd47 als research immunotherapy therapy collaboration iot

Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
Published: 2022-01-03 (Crawled : 16:00) - biospace.com/
ANVS | $11.88 3.39% 0.0% 230K

| -32.42% | O: 2.39% H: 10.22% C: 9.89%
conference biotech iot

Protalix BioTherapeutics Issues 2021 Letter to Stockholders
Published: 2021-12-22 (Crawled : 12:30) - biospace.com/
PLX | $1.2 1.7% 0.0% 270K

| 37.14% | O: -1.85% H: 5.61% C: 5.09%
therapeutics iot

AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
LCTX | $1.14 0.0% 330K

| -44.93% | O: 0.97% H: 0.0% C: 0.0%
AGE A | $11.1 0.0% 3.8K

| 1485.71% | O: 1.43% H: 1.39% C: -1.42%
multiple sclerosis license technology therapeutics biotech sclerosis iot

Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
PLX | $1.2 1.7% 0.0% 270K

| 5.73% | O: -3.08% H: 0.0% C: 0.0%
financial results results iot

Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K

| -9.61% | O: 2.08% H: 0.0% C: 0.0%
immunotherapy solid tumors therapy cancer iot conference her2+ her2- her2

Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021
Published: 2021-11-08 (Crawled : 13:00) - biospace.com/
PLX | $1.2 1.7% 0.0% 270K

| 8.11% | O: 0.9% H: 3.57% C: 1.79%
financial results results iot

Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series
Published: 2021-10-25 (Crawled : 11:00) - globenewswire.com
MTNB | $0.1815 0.83% -0.61% 770K

| -84.07% | O: -0.88% H: 0.89% C: -2.68%
biopharma biotech growth iot

Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
MTNB | $0.1815 0.83% -0.61% 770K

| -84.21% | O: 0.0% H: 4.39% C: 2.63%
biopharma phase 1 potential drug iot phase 2 phase 3

Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
Published: 2021-10-18 (Crawled : 17:00) - biospace.com/
LCTX | $1.14 0.0% 330K

| -51.49% | O: -1.28% H: 1.72% C: -1.72%
biotech growth iot

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease
Published: 2021-10-15 (Crawled : 13:00) - prnewswire.com
PLX | $1.2 1.7% 0.0% 270K

| -4.0% | O: -2.4% H: 3.28% C: 0.82%
disease treatment iot trial prx012 rare

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease
Published: 2021-10-11 (Crawled : 11:00) - prnewswire.com
PLX | $1.2 1.7% 0.0% 270K

| -10.78% | O: -12.27% H: 4.24% C: -1.69%
disease treatment iot prx012 rare

Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference
Published: 2021-10-01 (Crawled : 14:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K

| -21.44% | O: -0.45% H: 1.47% C: -2.72%
presentation immunotherapy blood solid tumors therapy cancer iot conference

Panakès Partners Appoints Dr. Rob Woodman As Partner To Lead Biotech Investment
Published: 2021-09-27 (Crawled : 07:00) - prnewswire.com
PHGE | $0.3465 17.42% 1.01% 220K